Indication: Breast Cancer

A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced or metastatic breast cancer

Advanced or Metastatic HR+ / HER2-

Sub-indication: ER+ breast cancer- Second line or third line (as long as no more than one previous chemotherapy), patient had to have been treated previously after they were metastatic.

Line of Therapy: 2nd or 3rd Line

Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: GlaxoSmithKline

Learn more at ClinicalTrials.gov

Email for more information: Breast-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.